Navigation Links
New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C
Date:12/3/2009

se/hepatitis/Hepc.pdf '>http://www.who.int/csr/disease/hepatitis/Hepc.pdf

[2] American Association for the Study of Liver Diseases - http://www.aasld.org/patients/Pages/LiverFastFactsHepC.aspx

    [3] World Health Organization -
http://www.who.int/csr/disease/hepatitis/Hepc.pdf

[4] The chimpanzee is the only animal other than humans that is susceptible to HCV

[5] Lanford et al, Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection, Science online

    Media Contact:

    Navjot Rai
    Santaris Pharma A/S
    Office: +1-858-764-7064 ext. 206
    Cell: +1-619-723-5450
    e-mail: navjot.rai@santaris.com

SOURCE Santaris Pharma A/S


'/>"/>
SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... N.C. , Aug. 1, 2014  With monumental ... learning to speak a second language. Clinical efficacy is ... agencies established under the ACA like PCORI are directing ... a variety of new entities and environments, the federal ... speak the new language of outcomes and managed markets ...
(Date:8/1/2014)... WASHINGTON , Aug. 1, 2014 In ... of treatments for sexual dysfunction, more than 60 doctors ... penned an open letter questioning the Food and Drug ... the most common form of male sexual dysfunction compared ... on the agency to act for women by approving ...
(Date:8/1/2014)... According to the new ... Anti infective), Basic (Films, Cleansing), Advanced (Hydrogels, Hydrocolloids, ... Pressure Relief Devices, NPWT) - Global Forecast to ... is expected to reach $18.3 Billion by 2019 ... CAGR of 3.2% from 2014 to 2019. ...
Breaking Medicine Technology:Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 360+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3
... Banner Health and ... jointly announce Banner Health,s system-wide conversion to Masimo rainbow® SET ... Health hospital will be cared for using the most technologically ... "The decision to convert our entire hospital system ...
... 2, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Medicine Technology:Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 2Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 3Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 4Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 5Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 6Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 2Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 3Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 4Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 5Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 6Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 7Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 8
(Date:8/1/2014)... use among young people has spiked, with 29.3 percent ... at least once and 17 percent admitting to regular use ... ‘Yes to Life,’ volunteers from the Church of Scientology of ... information about drugs, to help reverse this alarming trend. , ... Say ‘Yes’ to Life,” volunteers have distributed 40,000 copies of ...
(Date:8/1/2014)... appetite and whole-body metabolism. A protein known as PPARγ ... and body weight, but the identity of the neurons ... new study in the Journal of Clinical Investigation ... neuron known as pro-opiomelanocortin (POMC) neurons is critical in ... and colleagues at Yale University School of Medicine found ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- The U.S. ... approved a new drug, Jardiance, to help fight type ... alone or added to existing treatment regimens to control ... Dr. Curtis Rosebraugh, director of the Office of Drug ... and Research, said in an agency statement. The ...
(Date:8/1/2014)... Summer is here, and with it comes the season of ... can be a pain for dogs. Animal Emergency & Referral ... get rid of ticks and prevent them completely. , Female ... which is why they are so active during this season. ... and carry a number of diseases, including lyme disease, babesiosis ...
(Date:8/1/2014)... of a cancer diagnosis may improve health outcomes for ... by a researcher at the University of Houston (UH). ... intervention is the writing instruction. Otherwise, writing is just ... journal can be therapeutic, but oftentimes we don,t get ... not," said Qian Lu, assistant professor and director of ...
Breaking Medicine News(10 mins):Health News:Addressing a Serious Issue Affecting German Teens 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:Tis the Season for Tick Prevention 2Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3
... Core Administration Software with ... PLANO, Texas, May 15 Perot Systems (NYSE:,PER) ... Core,Administration Software. Xcelys 5.0 software is a continuance of ... health plan market., Xcelys, formerly called PERADIGM software, ...
... of shingles cases, expert says , , THURSDAY, May ... older should be vaccinated against shingles, a condition that ... Disease Control and Prevention recommended on Thursday. , This ... 2006, after the ZOSTAVAX vaccine was approved by the ...
... pump inhibitors (PPIs) to control gastroesophageal reflux disease ... take them continue to experience breakthrough, which is ... regurgitation and heartburn. These breakthrough symptoms lead more ... (OTC) remedies, according to a survey recently conducted ...
... YORK, May 15 Pharmaceutical research and,development (R&D) is ... years and,a billion dollars of investment to turn a ... journey from discovery to market, is filled,with challenges. For ... makes it to the market. "From Molecule to Medicine," ...
... that,the U.S. Court of Appeals for the Federal Circuit ... District Court for the Central District of,California in the ... As a result of the Court of Appeals, ruling, ... Sanofi-aventis is considering all its legal options., While ...
... Diabetes,Wholesale (ADW), a discount provider of diabetic supplies, is ... network. ADW hopes to,expand its online reach and strengthen ... affiliate partners a percentage of every sale they refer.,Commissions ... our affiliate,program as a great way to cultivate an ...
Cached Medicine News:Health News:Perot Systems Announces the Launch of Xcelys(TM) 5.0 Software 2Health News:CDC Recommends Shingles Vaccine for Those Over 60 2Health News:CDC Recommends Shingles Vaccine for Those Over 60 3Health News:Nearly 40 percent of GERD patients taking PPIs experience recurring symptoms 2Health News:Nearly 40 percent of GERD patients taking PPIs experience recurring symptoms 3Health News:District Court Decision Affirmed in U.S. Lovenox(R) (enoxaparin sodium) Patent Infringement Case 2Health News:American Diabetes Wholesale Launches Affiliate Program 2
Microalbumin Linearity Control...
Total IgE Control...
The K-ASSAY Lipid Controls are assayed controls produced from fresh human sera to monitor the accuracy and precision of quantitative lipid determinations of human sera specimens....
The K-ASSAY hs-CRP Control Set is intended to be used as a consistent test sample of known concentrations for monitoring the performance of hs-CRP (high sensitive C-Reactive Protein) immunoturbimetri...
Medicine Products: